ABSTRACT
INTRODUCTION
A plasmacytoma is a discrete, solitary mass of neoplastic monoclonal plasma cells in either bone or soft tissue. Solitary plasmacytoma (SP) is a rare entity of plasma cell proliferative disorder and is a biopsy-proven tumor with evidence of clonal plasma cells and no evidence of other features of multiple myeloma (MM). There are 2 types of SP as determined by the location of the lesions: SP of bone and solitary extramedullary plasmacytoma. Solitary plasmacytoma of bone (solitary osseous plasmacytoma, SPB) is a localized tumor in the bone and occurs most frequently in the vertebral column. Solitary extramedullary plasmacytoma (solitary extraosseous plasmacytoma, SEP) arises outside the bone in soft tissues and occurs most frequently in the head and neck region, mainly in the upper aerodigestive tract. Multiple plasmacytomas are defined as the presence of more than one plasmacytoma (occurring concurrently or sequentially) in the absence of bone marrow evidence of MM. Extramedullary plasmacytoma can arise in patients with multiple myeloma (MM) at any time during the course of the disease (extramedullary MM, EMM) (Swerdlow et al. 2016) . SPB accounts for approximately 5% of plasma cell malignancies. SEP accounts for approximately 3% of plasma cell malignancies. The median age at diagnosis is 55 to 65 years in SPB and 55 to 60 years in SEP. In SPB, men are diagnosed twice as frequently as women. Approximately two-thirds of patients with SEP are male (Dores et al. 2009; Frassica et al. 1989; Shih et al. 1995) . A little more than half of patients with SPB will eventually develop overt MM and SPB had a poorer prognosis than SEP (Guo et al. 2013 ). For patients with SPB, median overall survival (OS) was approximately 10 years; 5-year OS rate was 75%; 10-year OS rate was 45%; 5-year disease-free survival (DFS) rate was 45% and 10-year DFS rate was 25% (Frassica et al. 1989 ). For patients with SEP, the median overall survival was 12.5 years; 5-year OS rate was 88% and 10-year OS rate was 55% (Creach et al. 2009 ). Patients with SEP involving the head and neck region had superior median survival when compared to patients with other sites of SEP (13 versus 4 years) (Gerry & Lentsch 2013) .
Adverse prognostic factors of SP for progression into MM are larger tumor size (≥5 cm), serum β2 microglobulin >3.5 mg/L, persistence of serum M-protein after radiation therapy (Galieni et al. 1995) and SEP with minimal marrow involvement. Other reported predictors for progression to MM include the presence of osteopenia, reduction in uninvolved immunoglobulin levels (Jackson & Scarffe 1991) and the presence of high-grade angiogenesis in the tumor sample (Kumar et al. 2003) .
The treatment of choice for SEP is radiation therapy, given with curative intent at a dose of 40 to 50 Gy over four weeks (Creach et al. 2009 ). For patients with an incompletely resected SEP after diagnostic biopsy, local radiation therapy is recommended rather than further surgery, chemotherapy or observation (Grade 1C). For patients with completely resected SEP after diagnostic biopsy, observation is recommended rather than adjuvant radiation therapy or chemotherapy (Grade 2C) (Soutar et al. 2004 ). The treatment of choice for SPB is localized radiation therapy, given at a dose of 40 to 50 Gy over four weeks, directed at the tumor site (Grade 1C) (Reed et al. 2011) , whereas the standard treatment for MM is systemic therapy.
We report an interesting case of solitary plasmacytoma, which showed the classical spectrum of plasma cell proliferative disorder, i.e., recurrences of plasmacytoma and then evolution into multiple plasmacytomas.
CASE REPORT
In 2003, a 56-year-old man, with hypertension and ischemic heart disease, presented with the 5-month-history of right nasal obstruction and intermittent epistaxis. He had solitary extramedullary plasmacytoma of the nasopharynx (3.5 × 2 × 2.5 cm) (Figure 1) , with no paraproteinaemia. He received radical radiotherapy (56 Gy) to the nasopharynx, achieving complete remission.
Ten years later, in 2014, he had recurrence of plasmacytoma (osseous) in left tibia (10 × 6 cm) ( Figures  1 & 2) , presenting with pathological fracture. There was monoclonal paraproteinaemia (4.2 g/L, IgG lambda). He received radical radiotherapy (50 Gy) to left tibia, achieving partial response.
In July 2016, he had recurrence of plasmacytoma (osseous) in right tibia (Figure 1 ), presenting with 2-month-history of right leg pain and swelling. There was presence of monoclonal paraprotein (IgG lambda, 5.5 g/L in serum and 75 mg/L in urine). He received radical radiotherapy (45 Gy) to right tibia.
Just after completing radiotherapy to right tibia, in November 2016, he presented again with increasing in severity of pain in right leg. There was progressive swelling in the area around right eye, double vision and headache.
On examination, there were proptosis of right eye and swelling in right leg. Imaging scans showed multiple plasmacytomas at right frontal (5.6 × 4.9 × 5.3 cm) (SUV max: 2.7), left frontal (1.1 × 1.4 × 1.4 cm), left high frontal, left high posterior parietal, right occipital bones, both tibia (SUVmax: right 2.6, left 2.5) and hypermetabolic lytic lesions in both 4th metatarsal bones (SUVmax: right 2.7, left 2.1). The extra-axial mass at right frontal convexity extends inferiorly into the right orbital extraconal space causing proptosis of the right eye globe and displacement of the superior rectus muscle and the optic nerve inferiorly. There was erosion of the adjacent right frontal skull vault and orbital plate (Figure 1 ). The rest of the marrow metabolic activity was homogenously increased (SUVmax: 3.5). Nasopharynx had normal morphometabolic appearance (liver SUVmax: 3.5). Biopsy of right tibia showed osseous plasmacytoma (Table 1, Figure 2 ). Monoclonal paraprotein level was increasing in trend (IgG lambda, 6.3 g/L in serum and 104.7 mg/L FIGURE 1. Imaging showing plasmacytomas in urine). There were hypercalcemia (corrected calcium 2.62 mmol/L) and lytic bone lesions.
Bone marrow aspirate result showed 3% plasma cells with occasional plasma cells showing abnormal morphology such as flame shape and binuclearity. Bone marrow trephine sample was suboptimal. Conventional cytogenetic analysis of bone marrow sample showed normal male chromosome, 46,XY, with no clonal abnormality, however, fluorescence in situ hybridization (FISH) result was not available. He was treated as MM. In 2017, he was 70 years old and had multiple comorbidities such as hypertension, ischemic heart disease, diabetes mellitus and dyslipidemia. His ECOG (The Eastern Cooperative Oncology Group) performance status score (Oken et al. 1982 ) was 2. He was treated with Bortezomib-based therapy (Bortezomib-ThalidomideDexamethasone). Currently after one cycle of treatment, clinical improvement is achieved (serum paraprotein 4.1 g/L, urine paraprotein 20 mg/L, no more headache/ double vision/ proptosis/ hypercalcaemia) ( Table 1) .
DISCUSSION
SEPs are plasma cell tumors that arise outside of the bone marrow. Diagnosis of SEP is made based on the following features: biopsy-proven extramedullary tumor with evidence of clonal plasma cells; no lytic lesions in metastatic bone survey and either PET/CT or MRI of the spine and pelvis; no clonal plasma cells in bone marrow aspirate and biopsy; no anemia, hypercalcemia or renal insufficiency that could be attributed to a clonal plasma cell proliferative disorder (Rajkumar et al. 2006 ). The first presentation of our patient, i.e. SEP, demonstrated the typical presentation of SEP for age, gender and presenting symptoms. He received the standard therapy, i.e. radiotherapy, achieving complete remission and prolonged disease-free survival for 10 years.
At initial diagnosis of plasmacytoma, it is important to distinguish SP from other plasma cell dyscrasias, especially MM, for the purpose of prognosis and treatment. Evaluation of a patient with a suspected SP should include the full diagnostic work-up of MM, i.e. unilateral bone marrow aspiration and biopsy, metastatic bone survey and either a PET/CT scan or an MRI of entire spine and pelvis, blood investigations such as complete blood count and differential with examination of peripheral blood smear, serum calcium, creatinine, albumin, lactate dehydrogenase, beta-2 microglobulin, and serum and urine protein electrophoresis with immunofixation, quantitation of immunoglobulins, serum free light chain assay, in addition to complete history and physical examination and tissue biopsy of the suspected lesion. In our patient, the diagnosis of SEP of the nasopharynx was made after the proper evaluation to exclude MM. Following the completion of therapy, it is important to have regular follow-up at periodic intervals to monitor for treatment complications and assess for possible relapse. Progression rate of SEP to MM is reported to be between 11 and 33% over 10 years (Cantone et al. 2017 ). For our patient, even though he achieved complete remission from the very first plasmacytoma, he still had been regular follow-up with the otorhinolaryngology team and haematology team, resulting in early detection and timely management of his recurrences of plasmacytomas. From literature review, there were similar case reports presenting the recurrence of plasmacytoma, highlighting the importance of regular long-term follow up to monitor the disease recurrence or progression to MM (Chang et al. 2014; Corvo et al. 2013) .
The recommendation for the frequency of visit is every three months for the first two years, then every six months for an additional three years, then yearly or every other year after five years. At each visit, the parameters to perform for monitoring are history and physical examination, urine and serum protein electrophoresis with immunofixation, complete blood count, serum creatinine and serum calcium. For patients with head and neck involvement, a fiberoptic endoscopy is performed at each MRI) should be repeated three to four months after completing therapy, and periodically thereafter. For all patients, CT or CT/PET or MRI (whichever imaging modality was used for the initial evaluation) should be performed every 6 to 12 months for the first five years after therapy. In our case, the patient was found to have multiple plasmacytomas involving critical sites and evolving into MM. It is crucial to be aware of timely intervention for complete diagnostic work-up in order to obtain the definitive diagnosis, especially for those with plasmacytoma involving critical sites such as eyes and central nervous system. Imaging technique like PET/CT scan plays an important role in timely detection of plasmacytoma with MM. This case report highlights the clinicians not to delay definitive treatment when plasmacytomas involves critical sites e.g. eyes, orbit, cranial nerves and spinal cord.
Bortezomib-based therapy followed by autologous haemopoietic stem cell transplantation (HSCT), whenever it is possible, is indicated for patients with solitary plasmacytoma who progressed into overt MM. For our patient, in view of age and multiple comorbidities, he was not eligible for HSCT and opted for Bortezomib-based therapy.
CONCLUSION
The importance of multi-disciplinary approach (otorhinolaryngology, radiotherapy and oncology, orthopedic, ophthalmology, haematology teams) for managing the patients with plasmacytoma is highlighted in order to achieve the holistic approach of management in terms of: thorough evaluation at presentation to rule out MM, choice of appropriate management (radiotherapy or systemic therapy) and regular long-term follow-up to monitor recurrence of SP or progression into overt MM.
